A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats. 1990

K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
Department of Pharmacy, Shimane Medical University Hospital, Izumo, Japan.

In order to clarify the possibility of pharmacokinetic interaction between quinolone and fenbufen, the plasma concentration-time profiles and serum protein binding of enoxacin, fenbufen and its active metabolite, felbinac, were investigated in rats. The rats were administered an intravenous dose of enoxacin (5 mg/kg) and fenbufen (10 mg/kg) alone or concomitantly. Coadministration with fenbufen tended to prolong the plasma elimination half-life of enoxacin by about 20%, whereas it showed no effect on the area under plasma concentration-time curve, total body clearance or distribution volume of enoxacin. The extent of enoxacin binding to rat serum tended to be slightly reduced by fenbufen in vivo and in vitro. Plasma concentration-time curves, pharmacokinetic parameters and serum protein binding of fenbufen and felbinac were not affected at all by the coadministration with enoxacin. These aspects suggest that there may be only a minor possibility of the pharmacokinetic interaction between enoxacin and fenbufen.

UI MeSH Term Description Entries
D008297 Male Males
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D010654 Phenylbutyrates Derivatives of 4-phenylbutyric acid, including its salts and esters.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015365 Enoxacin A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID. AT-2266,CI-919,Enoxacin Sesquihydrate,Enoxin,Enoxor,PD-107779,Penetrex,AT 2266,AT2266,CI 919,CI919,PD 107779,PD107779,Sesquihydrate, Enoxacin

Related Publications

K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
August 1994, Journal of clinical pharmacy and therapeutics,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
July 1987, Clinical pharmacology and therapeutics,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
June 1988, International journal of clinical pharmacology, therapy, and toxicology,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
May 1989, Arzneimittel-Forschung,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
June 2005, Therapeutic drug monitoring,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
April 1988, The New Zealand medical journal,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
March 2020, Translational and clinical pharmacology,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
December 2006, Biopharmaceutics & drug disposition,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
June 2010, Drug metabolism and disposition: the biological fate of chemicals,
K Naora, and Y Katagiri, and N Ichikawa, and M Hayashibara, and K Iwamoto
January 1987, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!